<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../images/favicon.png" type="image/x-icon">
  <title>Pediatric HIV and AIDS</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="../style.css">
  <link rel="stylesheet" href="../notes.css">

</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="../index.html">
   <div class="home-navigation">
      mtr<span class="logo-dot">.</span>
    </div>
  </a>


    <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="../index.html">Home</a>
      </li>

      <li class="menu__item">
        <a class="menu__link" href="../about-temp2.html">About</a>
      </li>
    </ul>
  </nav>
  
      <!-- Toggle switch for dark mode -->
      <div class="dark-mode-toggle">
        <label class="switch-toggle">
            <input type="checkbox" id="dark-mode-toggle-checkbox">
            <span class="toggle-slider"></span>
        </label>
      </div>

      <!-- Progress Bar  -->
      <div id="progress-container">
        <div id="progress-bar"></div>
    </div>
      
<!-- SIDEBAR -->
<div id="sidebar" class="sidebar">
  <button id="closeSidebarBtn" class="btn toggle-btn close-btn">Close</button>
  <ul class="sidebar-menu toggle-menu">
    <!-- Add the list of topics dynamically using JavaScript -->
  </ul>
</div>

<!-- Toggle button to open the sidebar -->
<button id="toggleSidebarBtn" class="btn toggle-btn">&#9776;</button>

<!-- END OF SIDEBAR -->

  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="../contribute.html">Contribute here</a> </span>
    </div>


  <!-- TOPIC AND IMAGE CONTAINER  -->

  <h1>Pediatric HIV and AIDS</h1>


  <!-- END OF TOPIC AND IMAGE CONTAINER  -->
  


    <article class="notes">
        <a id='top'></a>
    <article>

          <!-- LEARNING OBJECTIVES CONTAINER  -->
              <div class="custom-card" id="custom-card-1">
                <div class="icon"><img src="../images/icons/light-bulb.png" alt="Icon" class="icon"></div>
                <div class="title"> 
                  <h2>What You Will Learn</h2>
                </div>
                <div class="line">
                  <p>After reading this note, you should be able to...</p>
                </div>
                <div class="content">
                  <ul>
                    <li><i>This content is not available yet.</i></li>
                </ul>
                </div>
                <div class="read-more" onclick="toggleContent('custom-card-1')">Read More üç™</div>
              </div>
            
          <!-- END OF LEARNING OBJECTIVES CONTAINER  -->
        
        
          <!-- SHOW AND HIDE OUTLINE CONTAINER  -->
            <div class="outline2">
        
              <input type="radio" name="control-2" id="show-2">
              <label for="show-2">üêµ&nbsp; &nbsp;Show Outline</label>
              <input type="radio" name="control-2" id="hide-2">
              <label for="hide-2">üôà&nbsp; &nbsp; Hide Outline</label>
              <div class="contents">
                <div class="icon-box">
                  <!-- Replace 'path/to/your/icon.png' with the actual path to your PNG icon -->
                  <img src="../images/icons/book.png" alt="Icon" class="icon">
                </div>
                <div id="tableOfContents">
                    <ol id="tocList"></ol>
                </div>
              </div>
             <div>
        
        <!-- END OF SHOW AND HIDE OUTLINE CONTAINER  -->
        
        
          <br>
        
            <!-- BEGINNING OF NOTE -->
        
      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li><b>Human Immunodeficiency Virus (HIV)</b> is a lentivirus that targets and alters the immune system, increasing the risk and impact of other infections and diseases.</li>
              <li>Without treatment, it might progress to an advanced disease stage known as <b>Acquired Immune Deficiency Syndrome (AIDS)</b>.</li>
              <li>Current trends in the management of HIV infection have led to a substantial decrease in the incidence of new HIV infections and AIDS in children.</li>
              <li>Globally, there has been an estimated <b>58% decline</b> in newly infected children since 2001.</li>
              <li>These advancements have dramatically increased the ability to prevent and control this menace.</li>
            </ul>
            
            <h4>Where did HIV come from?</h4>
            <ul>
              <li>Scientists identified a type of chimpanzee in <b>West Africa</b> as the source of HIV infection in humans.</li>
              <li>They believe that <b>Simian Immunodeficiency Virus (SIV)</b> most likely transmitted to humans and mutated into HIV.</li>
              <li>Over decades, the virus spread slowly across Africa and later into other parts of the world.</li>
            </ul>
            
            <h4>HIV History</h4>
            <ul>
              <li>The earliest known case in a human was detected in a blood sample of a man in <b>Kinshasa, Republic of Congo</b>.</li>
              <li><b>June 1981</b> ‚Äì 5 cases of <b>Pneumocystis carinii pneumonia</b> were described in homosexual men in Los Angeles.</li>
              <li><b>December 1982</b> ‚Äì Vertical transmission of HIV was reported in 4 infants.</li>
              <li><b>March 1983</b> ‚Äì The virus was discovered, initially termed <b>HTLV-III/LAV</b>; 5 cases were reported in Africa.</li>
              <li><b>1985</b> ‚Äì Report of an infant infected with HIV through breastfeeding.</li>
            </ul>
            
            <h4>The Whirlwind Before Some Calm</h4>
            <ul>
              <li><b>HIV</b> ravaged the world, especially in <b>resource-limited countries</b>.</li>
              <li>Panic spread across countries, with infected people being stigmatized, and an increasing number of <b>AIDS orphans</b>.</li>
              <li>Death became a common occurrence, either due to the disease process or suicides by those who succumbed to social pressures, until the advent of <b>Highly Active Antiretroviral Therapy (HAART)</b> in 1986.</li>
            </ul>
            
            <h4>Burden</h4>
            <ul>
              <li>More than <b>90%</b> of adults and children with HIV infection live in <b>sub-Saharan Africa</b>, where the disease continues to have a devastating impact.</li>
              <li>Children experience more rapid disease progression than adults, with up to <b>50%</b> of untreated children dying within the <b>first 2 years</b> of life.</li>
            </ul>
            
            <h4>Why Africa?</h4>
            <ul>
              <li><b>Ignorance</b></li>
              <li><b>Poverty</b></li>
              <li><b>Accessibility</b></li>
              <li><b>Co-infections</b></li>
              <li>Some <b>sociocultural practices</b></li>
              <li><b>Conflict and wars</b></li>
              <li>Despite the decline, the <b>HIV incidence rate</b> still remains unacceptably high. These are some of the challenges peculiar to Africa that hinder efforts to curb this scourge. Nigeria, for instance, has the <b>6th largest tuberculosis burden</b> in the world.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'> Epidemiology and Structure of HIV</a>
          </h2>
        </header>
        <div class='body'>
            <h4>Transmission</h4>
            <ul>
              <li><b>Sexual contact</b>:
                <ul>
                  <li>Homosexual</li>
                  <li>Heterosexual</li>
                </ul>
              </li>
              <li><b>Parenteral exposure</b> to blood</li>
              <li><b>Percutaneous route</b></li>
              <li><b>Vertical transmission</b> (90-95%) - the primary route in children:
                <ul>
                  <li>Intrauterine</li>
                  <li>Intrapartum</li>
                  <li>Breastfeeding</li>
                </ul>
              </li>
            </ul>
            
            <h4>Virology</h4>
            <ul>
              <li>There are <b>2 types of HIV</b>:
                <ul>
                  <li><b>HIV-1</b>, which is found worldwide and is responsible for the global pandemic.</li>
                  <li><b>HIV-2</b>, found mainly in <b>West Africa, Mozambique,</b> and <b>Angola</b>. It is less pathogenic and makes little or no contribution to pediatric AIDS.</li>
                </ul>
              </li>
            </ul>
            
            <h4>HIV Structure</h4>
            <ul>
              <li>An outer double lipid layer derived from the host cell membrane</li>
              <li>Surface glycoprotein (<b>gp 120</b>)</li>
              <li>Transmembrane protein (<b>gp 41</b>)</li>
              <li>The core (capsid) is made of several proteins: <b>P24</b> (the main protein), <b>P17</b>, <b>P9</b>, and <b>P7</b></li>
            </ul>
            
            <h4>HIV Genome</h4>
            <ul>
              <li>2 copies of single-stranded RNA</li>
              <li>3 major sections:
                <ul>
                  <li><b>GAG region</b></li>
                  <li><b>POL region</b></li>
                  <li><b>ENV region</b></li>
                </ul>
              </li>
            </ul>
            
            <h4>HIV Genome</h4>
            <ul>
              <li><b>GAG region</b> - codes for viral core proteins:
                <ul>
                  <li>P24</li>
                  <li>P17</li>
                  <li>P9</li>
                  <li>P6</li>
                </ul>
              </li>
              <li><b>POL region</b> - codes for viral enzymes:
                <ul>
                  <li><b>Reverse Transcriptase (RT)</b></li>
                  <li><b>Integrase (IN)</b></li>
                  <li><b>Protease</b></li>
                </ul>
              </li>
              <li><b>ENV region</b> - codes for viral envelope proteins:
                <ul>
                  <li>gp120</li>
                  <li>gp41</li>
                </ul>
              </li>
            </ul>

                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/pediatric-hiv (1).jpg" alt="" onclick="openModal(this)">
                            <div class="caption">Structure of HIV</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Structure of HIV</div>
                          </div>
            

                          <h4>HIV Replication</h4>
                          <ul>
                            <li><b>Binding and Internalization</b></li>
                            <li><b>Reverse Transcription</b> & DNA incorporation</li>
                            <li><b>Transcription</b> & translation of viral genes</li>
                            <li><b>Assembly</b> and budding</li>
                          </ul>
                          
        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Life Cycle</a>
          </h2>
        </header>
        <div class='body'>

            <h4>Binding</h4>
            <ul>
              <li>HIV binds to cells via interaction between the HIV envelope glycoprotein and the host cell receptors (<b>CD4 molecule</b>) and co-receptors.</li>
              <li>The receptors are the <b>CD4 antigen</b> found on some lymphocytes, macrophages, monocytes, glial cells of the brain, fibroblasts, dendritic cells, and Langerhans cells.</li>
              <li>The major co-receptors are <b>CCR5</b> and <b>CXCR4</b> (and <b>CCR3</b>).</li>
              <li>Other proposed methods include:
                <ul>
                  <li>Non-neutralizing antiviral antibodies</li>
                  <li>Complement factors</li>
                  <li>Mannose-binding protein</li>
                  <li>DC-specific C-type lectin</li>
                </ul>
              </li>
            </ul>
            
            <h4>Fusion</h4>
            <ul>
              <li>The HIV envelope protein <b>gp120</b> binds to the host cell receptors and co-receptors on the outside of the cell.</li>
              <li>Insertion of <b>gp41</b> into the cell membrane of the host cell.</li>
              <li>Fusion of the two membranes.</li>
            </ul>
            
            <h4>Entry</h4>
            <ul>
              <li>The virus particle leaves its membrane behind (<b>uncoating</b>).</li>
              <li>The core of the virus is released into the cytoplasm of the host cell.</li>
              <li>Release of viral enzymes.</li>
            </ul>
            
            <h4>Reverse Transcription</h4>
            <ul>
              <li>For the virus to multiply, the viral (single-stranded) RNA must first be converted into (double-stranded) DNA.</li>
              <li>This is done by the viral enzyme <b>reverse transcriptase</b>.</li>
            </ul>
            
            <h4>Integration and Replication</h4>
            <ul>
              <li>The viral DNA is integrated into the host cell DNA by <b>integrase</b>.</li>
            </ul>
            
            <h4>Assembly and Maturation</h4>
            <ul>
              <li>Viral DNA is transcribed into <b>mRNA (messenger RNA)</b> with the help of the host‚Äôs enzymes.</li>
              <li>mRNA is transported to the cytoplasm where it is translated into protein precursors.</li>
              <li>Among the strands of messenger RNA produced by the cell are complete copies of HIV genetic material. These assemble with newly made HIV proteins and enzymes to form new viral particles, which are then released from the cell.</li>
              <li>The enzyme <b>protease</b> plays a vital role at this stage of HIV's life cycle by chopping up long strands of protein into smaller pieces, which are used to construct mature viral cores.</li>
            </ul>
            
            <h4>Budding</h4>
            <ul>
              <li>The provirus particles push through the cell membrane by budding, taking the lipid bilayer with them to form raw virus particles.</li>
              <li>This forms a mature virus, which is then ready to infect a new cell.</li>
            </ul>
            

                        <!-- image here -->
                        <div class="image-container">
                            <img src="../figures/pediatric-hiv (2).jpg" alt="" onclick="openModal(this)">
                            <div class="caption">Lifecycle of HIV</div>
                          </div>
                          
                          <div id="myModal" class="modal">
                            <span class="close" onclick="closeModal()">&times;</span>
                            <img class="modal-content" id="modalImage">
                            <div id="caption" class="caption">Lifecycle of HIV</div>
                          </div>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Pathogenesis of HIV</a>
          </h2>
        </header>
        <div class='body'>
            <ul>
              <li><b>Development of Quasi-Species:</b> HIV rapidly mutates, creating diverse viral populations within the host, which helps it evade the immune system.</li>
              <li><b>High Turnover of Virus and Role of Cytokines:</b> The virus replicates quickly, and cytokines (immune signaling molecules) play a role in this process.</li>
              <li><b>CD4 Cells Depletion:</b> HIV targets and depletes <b>CD4+ T cells</b>, which are crucial for immune function.</li>
              <li><b>Deterioration of the Immune System:</b> The loss of CD4+ T cells leads to a weakened immune system, making the body more susceptible to infections and diseases.</li>
            </ul>
            
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Clinical Features</a>
          </h2>
        </header>
        <div class='body'>

            <ul>
              <li>The clinical manifestations of HIV infection vary widely among <b>infants</b>, <b>children</b>, and <b>adolescents</b>:
                <ul>
                  <li><b>Asymptomatic</b></li>
                  <li><b>Non-specific</b></li>
                  <li><b>Recurrent infections</b></li>
                  <li><b>Opportunistic infections</b></li>
                  <li><b>Dermatological manifestations</b></li>
                  <li><b>CNS manifestations</b></li>
                  <li><b>Hematology/Oncology manifestations</b></li>
                  <li><b>AIDS defining illnesses</b></li>
                </ul>
              </li>
              <li><b>Clinical staging</b> is used along with <b>immunologic criteria</b> to determine when to initiate and how to monitor therapy.</li>
            </ul>
            
            <table class="note-table">
                <thead>
                <tr>
                <th>Adults and adolescents</th>
                <th>Children</th>
                </tr>
                  <tr>
                    <th colspan="2">Clinical Stage 1</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>
                      <ul>
                        <li>Asymptomatic</li>
                        <li>Persistent generalized lymphadenopathy</li>
                        <li>Performance scale 1: asymptomatic, normal activity</li>
                      </ul>
                    </td>
                    <td>
                      <ul>
                        <li>Asymptomatic</li>
                        <li>Persistent generalized lymphadenopathy</li>
                        <li>Performance scale 1: asymptomatic, normal activity</li>
                      </ul>
                    </td>
                  </tr>
                </tbody>
                <thead>
                  <tr>
                    <th colspan="2">Clinical Stage 2</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>
                      <ul>
                        <li>Weight loss, &lt;10% of body weight</li>
                        <li>Minor mucocutaneous manifestations (seborrhoeic dermatitis, fungal nail infections, recurrent oral ulcerations and angular chelitis)</li>
                        <li>Herpes zoster within the last five years</li>
                        <li>Recurrent upper respiratory tract infection (i.e. bacterial sinusitis)</li>
                        <li>And/or performance scale 2: symptomatic, normal activity</li>
                      </ul>
                    </td>
                    <td>
                      <ul>
                        <li>Unexplained persistent hepatosplenomegaly</li>
                        <li>Papular pruritic eruptions</li>
                        <li>Extensive wart virus infection</li>
                        <li>Extensive molluscum contagiosum</li>
                        <li>Recurrent oral ulcerations</li>
                        <li>Unexplained persistent parotid enlargement</li>
                        <li>Linear gingival erythema</li>
                        <li>Herpes zoster</li>
                        <li>Recurrent/chronic upper respiratory tract infection (otitis media, otorrhoea, sinusitis, tonsillitis)</li>
                        <li>Fungal nail infections</li>
                        <li>And/or performance scale 2: symptomatic, normal activity</li>
                      </ul>
                    </td>
                  </tr>
                </tbody>

  <thead>
    <tr>
      <th colspan="2">Clinical Stage 4</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>
        <ul>
          <li>HIV wasting syndrome</li>
          <li>Pneumocystis Jirovecii Pneumonia (PCP)</li>
          <li>Toxoplasmosis of the Central Nervous System</li>
          <li>Cryptococcus, extrapulmonary</li>
          <li>Cytomegalovirus disease of an organ other than liver, spleen or lymph node e.g retinitis</li>
          <li>Herpes simplex virus infection, mucocutaneous (>1 month) or visceral</li>
          <li>Progressive multifocal leucoencephalopathy</li>
          <li>Any disseminated endemic mycosis</li>
          <li>Candidiasis of esophagus, trachea and bronchi</li>
          <li>Lymphoma</li>
          <li>Kaposi's sarcoma</li>
          <li>HIV encephalopathy</li>
          <li>Extrapulmonary tuberculosis and/or perfomance scale 4: bedridden>50% of the day during last month</li>
          <li>Atypical disseminated leishmaniasis</li>
          <li>Disseminated non-tuberculous mycobacterial infection</li>
          <li>Chronic cryptosporidiosis</li>
        </ul>
      </td>
      <td>
        <ul>
          <li>Unexplained severe wasting, stunting<sup>b</sup> or severe malnutrition not responding to standard therapy</li>
          <li>Pneumocystis pneumonia</li>
          <li>Recurrent severe bacterial infections (e.g. empyema, pyomyositis, bone or joint infection but excluding pneumonia)</li>
          <li>Chronic Herpes simplex infection (oro-labial or cutaneous of >1 month, or visceral at any site)</li>
          <li>Extra-pulmonary TB</li>
          <li>Kaposi's sarcoma</li>
          <li>Oesophageal candidiasis (or candida of trachea, bronchi or lungs)</li>
          <li>Central nervous system toxoplasmosis (after the neonatal period)</li>
          <li>HIV encephalopathy</li>
          <li>CMV infection; retinitis or infection affecting another organ with onset >1 month)</li>
          <li>Extra-pulmonary cryptococcosis (including meningitis)</li>
          <li>Disseminated endemic mycosis (extra-pulmonary histoplasmosis, coccidiomycosis)</li>
          <li>Chronic cryptosporidiosis (with diarrhoea)</li>
        </ul>
      </td>
    </tr>
  </tbody>
</table>

<br>



                        <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (3).jpg" alt="" onclick="openModal(this)">
                <div class="caption">Extensive anal warts</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Extensive anal warts</div>
              </div>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (1).png" alt="" onclick="openModal(this)">
                <div class="caption">Popular pruritic eruptions</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Popular pruritic eruptions</div>
              </div>

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (2).png" alt="" onclick="openModal(this)">
                <div class="caption">Extensive molluscum contagiosum</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Extensive molluscum contagiosum</div>
              </div>


                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (3).png" alt="" onclick="openModal(this)">
                <div class="caption">Oral hairy leukoplakia</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Oral hairy leukoplakia</div>
              </div>

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (4).png" alt="" onclick="openModal(this)">
                <div class="caption">Kaposi sarcoma</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Kaposi sarcoma</div>
              </div>

                          <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (5).png" alt="" onclick="openModal(this)">
                <div class="caption">HIV wasting syndrome</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">HIV wasting syndrome</div>
              </div>

              
        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Classification of HIV-Associated Clinical Disease</a>
          </h2>
        </header>
        <div class='body'>



            <br>

                <table class="note-table">
                <thead>
                    <tr>
                    <th><b>HIV-Associated Clinical Disease</b></th>
                    <th><b>WHO Clinical Stage</b></th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                    <td>Asymptomatic</td>
                    <td>1</td>
                    </tr>
                    <tr>
                    <td>Mild</td>
                    <td>2</td>
                    </tr>
                    <tr>
                    <td>Severe</td>
                    <td>3</td>
                    </tr>
                    <tr>
                    <td>Advanced</td>
                    <td>4</td>
                    </tr>
                </tbody>
                </table>

                <br>

                <table class="note-table">
                <thead>
                    <tr>
                    <th colspan="7">HIV Infection Stage* Based on Age-Specific CD4+ T-Lymphocyte Count or CD4+ T-Lymphocyte Percentage of Total Lymphocytes</th>
                    </tr>
                    <tr>
                    <th rowspan="4">Stage</th>
                    <tr>
                        <th colspan="6">Age on Date of CD4+ T-Lymphocyte Test</th>
                    </tr>
                    <th colspan="2"> &lt;1</th>
                    <th colspan="2">1-5 Yr</th>
                    <th colspan="2">‚â•6 Yr</th>
                    </tr>
                    <tr>
                    <th>CELLS/ŒºL</th>
                    <th>%</th>
                    <th>CELLS/ŒºL</th>
                    <th>%</th>
                    <th>CELLS/ŒºL</th>
                    <th>%</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                    <td>1</td>
                    <td>‚â•1,500</td>
                    <td>‚â•34</td>
                    <td>‚â•1,000</td>
                    <td>‚â•30</td>
                    <td>‚â•500</td>
                    <td>‚â•26</td>
                    </tr>
                    <tr>
                    <td>2</td>
                    <td>750-1,499</td>
                    <td>26-33</td>
                    <td>500-999</td>
                    <td>22-29</td>
                    <td>200-499</td>
                    <td>14-25</td>
                    </tr>
                    <tr>
                    <td>3</td>
                    <td>&lt;750</td>
                    <td>&lt;26</td>
                    <td>&lt;500</td>
                    <td>&lt;22</td>
                    <td>&lt;200</td>
                    <td>&lt;14</td>
                    </tr>
                </tbody>
                </table>
                <p><small>*Stage is based primarily on the CD4+ T-lymphocyte count. The CD4+ T-lymphocyte count takes precedence over the CD4+ T-lymphocyte percentage, and the percentage is considered only if the count is missing.</small></p>
                <p><small>From Centers for Disease Control and Prevention: Revised surveillance case definition for HIV infection‚ÄîUnited States, 2014. MMWR 63(No. RR-3):1-10, 2014.</small></p>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'> AIDS-Defining Illnesses</a>
          </h2>
        </header>
        <div class='body'>

            <h4>Infections</h4>
            <ul>
            <li><b>Bacterial Infections</b>
                <ul>
                <li>Multiple or recurrent</li>
                <li>Mycobacterium Avium complex or Mycobacterium kansasii, disseminated or extrapulmonary</li>
                <li>Mycobacterium tuberculosis of any site (pulmonary, disseminated, or extrapulmonary)</li>
                <li>Mycobacterium, other species or unidentified species, disseminated or extrapulmonary</li>
                <li>Salmonella septicemia, recurrent</li>
                </ul>
            </li>
            <li><b>Fungal Infections</b>
                <ul>
                <li>Candidiasis of bronchi, trachea, or lungs</li>
                <li>Candidiasis of esophagus</li>
                <li>Coccidioidomycosis, disseminated or extrapulmonary</li>
                <li>Cryptococcosis, extrapulmonary</li>
                <li>Histoplasmosis, disseminated or extrapulmonary</li>
                <li><b>Pneumocystis jiroveci</b> (previously known as Pneumocystis carinii) pneumonia</li>
                </ul>
            </li>
            <li><b>Parasitic Infections</b>
                <ul>
                <li>Cryptosporidiosis, chronic intestinal (>1 month duration)</li>
                <li>Toxoplasmosis of brain, onset at age >1 month</li>
                </ul>
            </li>
            </ul>

            <h4>Neoplasms</h4>
            <ul>
            <li><b>Cancer</b>
                <ul>
                <li>Cervical cancer, invasive</li>
                <li>Kaposi sarcoma</li>
                <li>Lymphoma, Burkitt (or equivalent term)</li>
                <li>Lymphoma, Immunoblastic (or equivalent term)</li>
                <li>Lymphoma, primary, of brain</li>
                </ul>
            </li>
            </ul>


            <h4>Viral Infections</h4>
            <ul>
            <li><b>Cytomegalovirus (CMV)</b>
                <ul>
                <li>Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month</li>
                <li>Cytomegalovirus retinitis (with loss of vision)</li>
                </ul>
            </li>
            <li><b>Herpes Simplex Virus</b>
                <ul>
                <li>Chronic ulcers (>1 month duration)</li>
                <li>Bronchitis, pneumonitis, or esophagitis (onset at age >1 month)</li>
                </ul>
            </li>
            </ul>

            <h4>Neurological Disorders</h4>
            <ul>
            <li><b>HIV-Related Encephalopathy</b>
                <ul>
                <li>Encephalopathy attributed to HIV</li>
                <li>Progressive multifocal leukoencephalopathy</li>
                </ul>
            </li>
            </ul>

            <h4>General Conditions</h4>
            <ul>
            <li><b>Recurrent Pneumonia</b>
                <ul>
                <li>Pneumonia, recurrent</li>
                </ul>
            </li>
            <li><b>Wasting Syndrome</b>
                <ul>
                <li>Wasting syndrome attributed to HIV</li>
                </ul>
            </li>
            </ul>

        </div>
      </section>

      <section id='header-8'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'> Clinical Course of the Disease</a>
          </h2>
        </header>
        <div class='body'>
           

            <ul>
            <li><b>Rapid Progressors</b>
                <ul>
                <li><b>25-30%</b> (In developing countries)</li>
                <li>Onset of symptoms in the <b>first few months of life</b></li>
                <li>Median survival of <b>6-9 months</b></li>
                <li>Die by age <b>1 year</b></li>
                <li>Usually acquire the infection in <b>utero</b> or during the early perinatal period</li>
                </ul>
            </li>
            <li><b>Slower Progression of the Disease</b>
                <ul>
                <li><b>50-60%</b></li>
                <li>Perinatally infected</li>
                <li>Median age of survival <b>6 years</b></li>
                </ul>
            </li>
            <li><b>Long Term Survivors</b>
                <ul>
                <li><b>5-25%</b> of perinatally infected children</li>
                <li>Minimal or no progression of the disease</li>
                <li>Relatively normal <b>CD4 count</b></li>
                <li>May live beyond <b>8 years</b></li>
                </ul>
            </li>
            </ul>

        </div>
      </section>

            <section id='header-9'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'>Evaluation and Diagnosis </a>
          </h2>
        </header>
        <div class='body'>
                <h4>Initial Evaluation</h4>
                <ul>
                <li><b>Confirmation of HIV Infection</b></li>
                <li><b>Clinical Evaluation of the Child</b>
                    <ul>
                    <li>Detailed history and physical examination</li>
                    <li>Determination of immunization status</li>
                    <li>Anthropometry (weight, height/length, MUAC, head circumference)</li>
                    <li>Neuro-developmental assessment</li>
                    </ul>
                </li>
                <li><b>Immunological Evaluation of the Child</b> (CD4+ count/CD4+%)</li>
                <li>Review of other laboratory results</li>
                <li>Development of child-specific adherence strategy</li>
                </ul>

                <h4>Diagnosis</h4>
                <ul>
                <li><b>Index of Suspicion</b></li>
                <li><b>Indirect Testing</b>
                    <ul>
                    <li>Antibody assay
                        <ul>
                        <li>Serial</li>
                        <li>Parallel</li>
                        </ul>
                    </li>
                    </ul>
                </li>
                <li><b>Presumptive Diagnosis</b></li>
                <li><b>Current Trends in Diagnosis</b>
                    <ul>
                    <li>Early infant diagnosis</li>
                    <li>Diagnosis in older children
                        <ul>
                        <li>Indirect</li>
                        <li>Direct</li>
                        </ul>
                    </li>
                    </ul>
                </li>
                </ul>

            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (6).png" alt="" onclick="openModal(this)">
                <div class="caption">Antibody assay</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Antibody assay</div>
              </div>

            <h4>Presumptive Diagnosis in Early Infants</h4>
            <ul>
            <li><b>Infant is Confirmed HIV Antibody Positive</b>
                <ul>
                <li>Any <b>Stage 4</b> or <b>AIDS-indicator condition</b></li>
                <li>Recurrent <b>bacterial infections</b></li>
                </ul>
            </li>
            <li><b>Other Factors That Support the Diagnosis</b>
                <ul>
                <li>Recent <b>HIV-related maternal death</b></li>
                <li>Advanced <b>HIV disease in the mother</b></li>
                </ul>
            </li>
            </ul>

            <h4>Current Trends in Diagnosis</h4>
            <ul>
            <li><b>HIV RNA PCR</b>
                <ul>
                <li>Detects <b>viral RNA</b></li>
                <li>Lower sensitivity and specificity than <b>DNA PCR</b> in infants</li>
                <li>May be affected by <b>antiretroviral therapy</b></li>
                </ul>
            </li>
            <li><b>HIV Culture</b>
                <ul>
                <li>Just as sensitive as <b>HIV DNA PCR</b></li>
                <li>More <b>expensive</b>, <b>risky</b></li>
                <li>Long <b>turnaround time</b></li>
                </ul>
            </li>
            <li><b>P24 Antigen</b>
                <ul>
                <li>Least <b>sensitive</b> of all tests</li>
                <li>Should not be used for diagnosis, especially in infants under <b>1 month</b></li>
                <li>High <b>false positive rate</b> but newer test: <b>Ultrasensitive p24 Ag [Up24 Ag]</b> is more sensitive</li>
                </ul>
            </li>
            <li><b>Surrogate Markers</b>
                <ul>
                <li><b>Neopterin</b></li>
                <li><b>Beta-2 microglobulin</b></li>
                <li><b>HIV DNA PCR</b>
                    <ul>
                    <li>Highly <b>sensitive</b></li>
                    <li>Preferred method in infants <b>< 18 months</b></li>
                    </ul>
                </li>
                <li><b>Reverse Transcriptase-PCR</b>
                    <ul>
                    <li>Detects and quantifies the amount of <b>HIV RNA</b> in plasma</li>
                    </ul>
                </li>
                </ul>
            </li>
            </ul>





                                <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (7).png" alt="" onclick="openModal(this)">
                <div class="caption">DBS technique:  whole blood on filter paper</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">DBS technique:  whole blood on filter paper</div>
              </div>


                    <h4>Current Recommendations on Diagnosis</h4>

                    <ul>
                    <li><b>Age < 18 Months</b>
                        <ul>
                        <li><b>Rapid Test</b></li>
                        <li><b>DBS at 4-6 weeks</b></li>
                        <li><b>DBS 6 weeks after cessation of breastfeeding</b></li>
                        <li>Presumptive diagnosis in the absence of <b>virological tests</b> *</li>
                        </ul>
                    </li>
                    <li><b>Age > 18 Months</b>
                        <ul>
                        <li><b>Rapid Test</b></li>
                        </ul>
                    </li>
                    <li><b>Breastfeeding Child</b> *
                        <ul>
                        <li><b>Direct virological test</b></li>
                        </ul>
                    </li>
                    </ul>


                            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (8).png" alt="" onclick="openModal(this)">
                <div class="caption">Diagnosing HIV in Children</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Diagnosing HIV in Children</div>
              </div>

<h4>Provider-Initiated HIV Testing and Counselling (PITC)</h4>
<ul>
  <li>Offered to all children seen in health services because:
    <ul>
      <li>Features of HIV infection are often <b>non-specific</b></li>
      <li>HIV disease progresses faster with <b>higher mortality</b></li>
      <li>The ‚Äú<b>three C‚Äôs</b>‚Äù ‚Äì <b>Consent</b>, <b>Counselling</b>, and <b>Confidentiality</b> must be observed</li>
    </ul>
  </li>
  <li>Adopts an ‚Äú<b>opt-out</b>‚Äù approach: Caregivers and adolescents must specifically decline after pre-test information if they don‚Äôt want testing.</li>
</ul>



<h4>Ancillary Investigations</h4>

<ul>
  <li><b>Immunological Tests</b>
    <ul>
      <li>CD4 Count / %CD4 Count</li>
      <li>Viral Load</li>
    </ul>
  </li>
  <li><b>Microbiological Tests</b>
    <ul>
      <li>Tuberculin Skin Test</li>
      <li>Sputum/Gastric Aspirate for AAFB</li>
      <li>Gene Expert</li>
      <li>Blood Culture</li>
      <li>CSF Analysis</li>
      <li>Swab MCs</li>
      <li>HBV & HCV Screen</li>
    </ul>
  </li>
  <li><b>Radiological and Imaging</b>
    <ul>
      <li>Chest X-ray</li>
    </ul>
  </li>
  <li><b>Biochemical Tests</b>
    <ul>
      <li>Liver Function Tests (LFT)</li>
      <li>Electrolytes/Urea/Creatinine (E/U/Cr)</li>
      <li>Complete Blood Count (CBC)</li>
      <li>Serum Lipids</li>
      <li>Serum Amylase</li>
    </ul>
  </li>
  <li><b>Urine and Stool Tests</b>
    <ul>
      <li>Urinalysis</li>
      <li>Stool Studies</li>
    </ul>
  </li>
</ul>

        </div>
      </section>


      <section id='header-10'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-10'> Treatment</a>
          </h2>
        </header>
        <div class='body'>

<h4>Goals of Antiretroviral Therapy</h4>
<ul>
  <li><b>Eradication of HIV</b></li>
  <li><b>Reduction of HIV-associated morbidity</b></li>
  <li><b>Prolong duration and quality of survival</b></li>
  <li><b>Restore and preserve immunologic function</b></li>
  <li><b>Prevent HIV transmission</b></li>
</ul>

<h4>Treatment Modalities</h4>
<ul>
  <li><b>HAART Therapy</b>
    <ul>
      <li>Eligibility criteria</li>
      <li>Classes of ART</li>
      <li>Choosing a regimen</li>
      <li>Adherence</li>
      <li>Monitoring</li>
      <li>Treatment success</li>
      <li>Treatment failure</li>
      <li>2nd line drugs</li>
      <li>Complications of therapy</li>
    </ul>
  </li>
  <li><b>WHO ‚ÄúTreat-All‚Äù Recommendation (Geneva 2015)</b>
    <ul>
      <li>No limitations on eligibility (<b>28 million ‚Äì 37 million</b>)</li>
      <li>All populations, age groups, and stages</li>
      <li>Proposed benefits and limitations
        <ul>
          <li><b>Avert 21 million AIDS-related deaths</b></li>
          <li><b>Avert 28 million new infections by 2030</b></li>
        </ul>
      </li>
      <li>Expanded offer of pre-exposure prophylaxis</li>
      <li>New sets of targets for 2030 (<b>90:90:90</b>)
        <ul>
          <li><b>90%</b> of PLWHA being aware of their infection</li>
          <li><b>90%</b> of those diagnosed receiving HAART</li>
          <li><b>90%</b> of those on HAART having no detectable virus in their blood</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>


<h4>Classes of ART</h4>
<ul>
  <li><b>Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</b></li>
  <li><b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b></li>
  <li><b>Protease Inhibitors (PIs)</b></li>
  <li><b>New ART Classes</b>
    <ul>
      <li><b>Entry Inhibitors (HIV Fusion Inhibitors)</b></li>
      <li><b>Integrase Inhibitors</b></li>
      <li><b>Chemokine Receptor Antagonists</b></li>
      <li><b>Maturation Inhibitors</b></li>
    </ul>
  </li>
</ul>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (9).png" alt="" onclick="openModal(this)">
                <div class="caption">HAART THERAPY and sites of action</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">HAART THERAPY and sites of action</div>
              </div>

<table class="note-table">

  <tr>
    <th>Trade Name</th>
    <th>Abbrev</th>
    <th>Drug</th>
  </tr>
  <tr>
    <td>Epivir</td>
    <td>3TC</td>
    <td>Lamivudine*</td>
  </tr>
  <tr>
    <td>HIVID *</td>
    <td>ddC</td>
    <td>Zalcitabine</td>
  </tr>
  <tr>
    <td>Retrovir</td>
    <td>AZT</td>
    <td>Zidovudine*</td>
  </tr>
  <tr>
    <td>Viread</td>
    <td>TDF</td>
    <td>Tenofovir*</td>
  </tr>
  <tr>
    <td>Zerit</td>
    <td>d4T</td>
    <td>Stavudine*</td>
  </tr>
  <tr>
    <td>Ziagen</td>
    <td>ABC</td>
    <td>Abacavir*</td>
  </tr>
</table>

<br>

<table class="note-table">
<tr>
<th colspan="2">Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)</th>
</tr>
  <tr>
    <th>Abbrev</th>
    <th>Drug</th>
  </tr>
  <tr>
    <td>DLV</td>
    <td>Delavirdine</td>
  </tr>
  <tr>
    <td>EFV</td>
    <td>Efavirenz*</td>
  </tr>
  <tr>
    <td>NVP</td>
    <td>Nevirapine*</td>
  </tr>
  <tr>
    <td>ETV</td>
    <td>Etravirine</td>
  </tr>
</table>

<br>

<table class="note-table">
<tr>
<th colspan="3">Non-nucleoside Reverse Transcriptase Inhibitors (NRTIs)</th>
</tr>
  <tr>
    <th>Abbrev</th>
    <th>Drug</th>
  </tr>
  <tr>
    <td>TPV</td>
    <td>Tipranavir</td>
  </tr>
  <tr>
    <td>APV</td>
    <td>Amprenavir</td>
  </tr>
  <tr>
    <td>IDV</td>
    <td>Indinavir</td>
  </tr>
  <tr>
    <td>SQV</td>
    <td>Saquinavir</td>
  </tr>
  <tr>
    <td>LPV/r</td>
    <td>Lopinavir/ritonavir*</td>
  </tr>
  <tr>
    <td>RTV</td>
    <td>Ritonavir*</td>
  </tr>
  <tr>
    <td>ATV</td>
    <td>Atazanavir</td>
  </tr>
  <tr>
    <td>FPV</td>
    <td>Fosamprenavir</td>
  </tr>
  <tr>
    <td>NFV</td>
    <td>Nelfinavir*</td>
  </tr>
  <tr>
    <td>DRV</td>
    <td>Darunavir</td>
  </tr>
</table>

<br>

<h4>Receptor Blockers</h4>
<ul>
  <li><b>Maraviroc</b> (CCR5 receptor blocker)</li>
</ul>

<h4>Entry Inhibitor</h4>
<ul>
  <li><b>Enfurvitide</b></li>
</ul>

<h4>Integrase Inhibitors</h4>
<ul>
  <li><b>Raltegravir</b></li>
</ul>

<h4>Maturation Inhibitors</h4>
<ul>
  <li><b>Beviramat</b></li>
</ul>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (10).png" alt="" onclick="openModal(this)">
                <div class="caption">Choosing a regimen</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Choosing a regimen</div>
              </div>


<br>

<table class="note-table">
  <thead>
  <tr>
  <th colspan="5">Recommended first-line ART regimens for adults, adolescents, pregnant, breastfeeding women and children</th>
  </tr>
    <tr>
      <th>First-line ART</th>
      <th>Preferred first-line</th>
      <th>Alternative first-line regimens</th>
      <th>Special Circumstances</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Adults and Adolescents</td>
      <td>TDF + 3TC (or FTC) + DTG</td>
      <td>TDF + 3TC (or FTC) + EFV 400</td>
      <td>
        TAF + 3TC (or FTC) + DTG<br>
        ABC + 3TC + DTG<br>
        AZT + 3TC + EFV 400
      </td>
    </tr>
  </tbody>
</table>

<br>

<table class="note-table">
  <thead>
  <tr>
  <th colspan="5">Recommended First-line ART regimen for Children</th>
  </tr>
    <tr>
      <th>Weight (Kg)</th>
      <th>Age (years)</th>
      <th>Preferred First Line Regimen</th>
      <th>Alternative First Line Regimen</th>
      <th>Special Circumstances</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th colspan="5">Neonates</th>
    </tr>
    <tr>
      <td>&lt; 3kg</td>
      <td>&lt; 1 month</td>
      <td>AZT + 3TC + DTG* or RAL</td>
      <td>AZT + 3TC + LPV/r**</td>
      <td>AZT+3TC+NVP</td>
    </tr>
    <tr>
      <th colspan="5">Infants & Children</th>
    </tr>
    <tr>
      <td>&lt; 20kg</td>
      <td>&lt; 6years</td>
      <td>ABC +3TC + DTG</td>
      <td>
        ABC+3TC +LPV/r<br>
        AZT + 3TC +LPV/r<br>
        ABC (or AZT) +3TC+ RAL***
      </td>
      <td>
        ABC + 3TC +EFV**(or NVP)<br>
        AZT + 3TC + EFV (or NVP)
      </td>
    </tr>
    <tr>
      <td>20 ‚Äì 30kg</td>
      <td>6-10years</td>
      <td>
        ABC+3TC+DTG<br>
        Or<br>
        TDF****(TAF)***** + 3TC +DTG
      </td>
      <td>
        ABC+3TC +LPV/r<br>
        ABC +3TC + RAL
      </td>
      <td>AZT + 3TC + LPV/r (or RAL)</td>
    </tr>
  </tbody>
</table>

<p><small>
* DTG 50mg is recommended from four weeks of age and weighing ‚â•3kg, raltegravir (RAL) is recommended for use in neonates from birth to 4 weeks of age<br>
** LPV/r liquid can be used from two weeks of age (corrected gestational age of 42 weeks) at 1ml 12 hourly<br>
*** RAL is used for children aged 4 weeks to 3 years<br>
**** TDF is used from children with weight ‚â• 25kg<br>
***** TAF can be used in children aged 6years and above weighing ‚â• 25kg<br>
Note: Refer to National HIV/ART and STIs Guidelines for dosing of ARVs. AZT should be administered in instances of poor tolerability or administration challenges with DTG/s particularly in settings where the rapid acquisition of maternal treatment/viral load is unlikely and children at very high risk of carrying or INSTI resistance.
</small></p>


<h4>Routine Monitoring of Children on ART</h4>
<ul>
  <li><b>2 weeks</b> after commencement of therapy</li>
  <li><b>Monthly</b> for the first 3 months</li>
  <li>Thereafter <b>every 3 months</b> except otherwise indicated</li>
</ul>

<h4>Evaluation in Follow-Up Clinics</h4>
<ul>
  <li><b>Clinical Evaluation</b>:
    <ul>
      <li><b>Growth monitoring</b> using growth chart</li>
      <li><b>Physical examinations</b></li>
      <li><b>Developmental assessment</b></li>
      <li><b>Immunization status</b></li>
      <li><b>Nutritional assessment</b></li>
      <li><b>Psychosocial assessment</b></li>
      <li><b>Adverse ARV effects</b></li>
      <li>Review ARV dosages for every <b>10% increase in body weight</b></li>
    </ul>
  </li>
</ul>


<h4>Laboratory Evaluation</h4>
<ul>
  <li><b>CD4+ count</b> every 3 months (except otherwise indicated)</li>
  <li><b>Viral load</b> at 6 months (where available)</li>
  <li><b>FBC</b> at one month and every 3 months (except otherwise indicated)</li>
  <li><b>LFTs</b> at baseline and AST and ALT plus bilirubin levels every 3 months unless otherwise indicated (for patients on NVP, these should be done after 1 month of commencement)</li>
  <li><b>E/U, creatinine, and urinalysis</b> at baseline then every 3 months unless otherwise indicated</li>
  <li><b>Serum lipid profile and amylase</b> at baseline, at 3 months, and thereafter as indicated, where possible</li>
</ul>

<h4>Routine Monitoring of Children Who Are Not Yet Eligible for ART</h4>
<ul>
  <li>The evaluation of infants and children who are not yet eligible for ART should be performed <b>every 3 months</b></li>
  <li><b>Clinical evaluation</b></li>
  <li><b>Immunological evaluation</b> (CD4+ count/CD4+ %)</li>
  <li>Other investigations as clinically indicated</li>
</ul>

<h4>ART Treatment Success</h4>
<ul>
  <li><b>Reduction of viral load</b> of:
    <ul>
      <li>At least <b>1 log</b> by 6-8 weeks after initiation of treatment</li>
      <li><b>&lt; 400 cp/ml</b> at 24 months on therapy</li>
      <li>Sustained <b>&lt; 50 cp/ml</b></li>
    </ul>
  </li>
  <li><b>Undetectable</b> (&lt; 200 RNA copies/ml) viral load by 6 months</li>
  <li><b>Reduced MTCT</b></li>
  <li><b>Improved quality of life</b></li>
  <li><b>Reduced morbidity</b> from opportunistic infections</li>
</ul>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (11).png" alt="" onclick="openModal(this)">
                <div class="caption">Treatment failure algorithm</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Treatment failure algorithm</div>
              </div>


<h4>3rd Line Therapy</h4>
<ul>
  <li><b>Comprehensive assessment</b>
    <ul>
      <li>Adherence assessment</li>
    </ul>
  </li>
  <li><b>Consideration for third line</b>
    <ul>
      <li>Limited evidence to guide third-line strategies in resource-limited settings</li>
      <li>Considerations include:
        <ul>
          <li><b>Raltegravir/boosted Darunavir/Etravirine</b></li>
          <li>Optimized NRTI (dependent on genotype findings)</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

<h4>Supportive Care</h4>
<ul>
  <li><b>Social support</b></li>
  <li><b>Nutrition</b></li>
  <li><b>Routine dental evaluation and oral hygiene</b></li>
  <li><b>Pain management</b></li>
  <li><b>Developmental evaluation</b></li>
  <li><b>Immunization</b></li>
  <li><b>PCP prophylaxis</b></li>
  <li><b>Tuberculin testing</b></li>
  <li><b>Hand washing</b></li>
</ul>

<h4>Psychosocial Support</h4>
<ul>
  <li><b>Reassurance</b> on being accepted, care, attention, security, love, nurturing, play</li>
  <li><b>Supportive home environment</b></li>
  <li><b>Specific help</b> to overcome individual problems</li>
  <li><b>Simple, age-appropriate information</b> about loss of loved ones</li>
  <li><b>Avoid stigmatization</b></li>
</ul>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (12).png" alt="" onclick="openModal(this)">
                <div class="caption">Co-Trimoxazole preventive therapy</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Co-Trimoxazole preventive therapy</div>
              </div>

<h4>Palliative Care for the Terminally Ill Child</h4>
<ul>
  <li><b>Most challenging period</b> for parents/caregivers</li>
  <li><b>Caregivers need assistance</b> to ensure that the child receives dignified end-of-life care at home or in the hospital</li>
</ul>

        </div>
      </section>





      <section id='header-11'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-11'>Prevention </a>
          </h2>
        </header>
        <div class='body'>
<ul>
  <li>Follows mode of transmission:
    <ul>
      <li><b>Parenteral exposure to blood</b></li>
      <li><b>Percutaneous</b></li>
      <li><b>Sexual transmission</b></li>
      <li><b>MTCT</b> (Mother-To-Child Transmission)</li>
    </ul>
  </li>
  <li><b>Educate children</b> about potentially risky exposures/behaviours and how to avoid them</li>
  <li><b>Discuss reduction</b> of potentially risky behaviours as appropriate to their age</li>
  <li><b>Pre-exposure prophylaxis</b></li>
  <li><b>Post-exposure prophylaxis</b></li>
  <li><b>Limiting transmission by blood</b></li>
  <li><b>PMTCT</b> (Prevention of Mother-To-Child Transmission)</li>
</ul>

<h4>Universal Precaution</h4>
<ul>
  <li><b>Safe handling and disposal of sharps</b></li>
  <li><b>Use of personal protective equipment</b></li>
  <li><b>Decontaminating equipment</b></li>
  <li><b>Safe disposal of infectious waste material</b></li>
  <li><b>Safe environmental practices</b></li>
</ul>


<h4>Pre-Exposure Prophylaxis (PrEP)</h4>
<ul>
  <li>Providing oral ARVs to uninfected individuals prior to HIV exposure is known as <b>pre-exposure prophylaxis (PrEP)</b></li>
  <li>PrEP has been demonstrated to be effective among:
    <ul>
      <li><b>Men who have sex with men (MSM)</b></li>
      <li>Individuals exposed to the virus through <b>heterosexual sex</b></li>
    </ul>
  </li>
</ul>

<h4>Post-Exposure Prophylaxis (PEP)</h4>
<ul>
  <li><b>Occupational hazards</b></li>
  <li><b>Victims of sexual assault</b></li>
</ul>


            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (4).jpg" alt="" onclick="openModal(this)">
                <div class="caption">4 prongs of PMTCT</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">4 prongs of PMTCT</div>
              </div> 

<H4>Primary prevention of HIV infection among women of reproductive age</H4>
            <!-- image here -->
            <div class="image-container">
                <img src="../figures/pediatric-hiv (13).png" alt="" onclick="openModal(this)">
                <div class="caption">Primary prevention of HIV infection among women of reproductive age</div>
              </div>
              
              <div id="myModal" class="modal">
                <span class="close" onclick="closeModal()">&times;</span>
                <img class="modal-content" id="modalImage">
                <div id="caption" class="caption">Primary prevention of HIV infection among women of reproductive age</div>
              </div>


<ul>
              <li>Early diagnosis and treatment of STIs</li>

  <li><b>STI treatment services</b> present a good opportunity to provide information on:
    <ul>
      <li><b>HIV infection</b></li>
      <li><b>Mother-to-Child Transmission (MTCT)</b></li>
      <li><b>Referral for HIV Testing and Counseling (HTC)</b></li>
      <li><b>Condom use</b> and <b>effective contraception</b> for dual protection from HIV and other STIs</li>
    </ul>
  </li>
</ul>


<h4>Prevent Unwanted Pregnancies Among Women Living with HIV</h4>
<ul>
  <li><b>Contraception</b>
    <ul>
      <li><b>Barrier methods</b></li>
      <li><b>Oral contraceptives</b></li>
      <li><b>Injectables</b></li>
    </ul>
  </li>
  <li><b>Planned pregnancy</b></li>
  <li><b>Issues of discordant couples</b></li>
</ul>

<h4>Prevent HIV Transmission from Women Living with HIV to Their Infants</h4>
<ul>
  <li><b>Identifying HIV-infected women</b></li>
  <li><b>Reducing maternal viral load (VL) with ARV prophylaxis or treatment</b></li>
  <li><b>Reducing viral exposure by safer delivery practices</b></li>
  <li><b>ARV prophylaxis for the infant</b></li>
  <li><b>Reducing infant exposure to the virus through infant-feeding counseling</b></li>
</ul>

<h4>Follow-Up Visit</h4>
<ul>
  <li><b>HIV-exposed babies should be seen:</b>
    <ul>
      <li>Every 2 weeks for the first 6 weeks, then</li>
      <li>Every 4 weeks until confirmation of HIV status, or</li>
      <li>As indicated.</li>
    </ul>
  </li>
</ul>

<h4>Provide Appropriate Treatment, Care, and Support</h4>
<ul>
  <li><b>To mothers living with HIV:</b>
    <ul>
      <li>Their health and future</li>
      <li>The health and nutrition of their children</li>
      <li>The welfare of their families</li>
    </ul>
  </li>
</ul>


        </div>
      </section>





      <hr style="margin: 3rem 0;">

      <!-- PRACTICE QUESTIONS CONTAINER -->

      <div class="custom-card" id="custom-card-2">
        <div class="icon"><img src="../images/icons/practice-questions.png" alt="Icon" class="icon"></div>
        <div class="title"> 
          <h2>Practice Questions</h2>
        </div>
        <div class="line">
          <p>Check how well you grasp the concepts by answering the following questions...</p>
        </div>
        <div class="content">
          <ol>
            <li><i>This content is not available yet.</i></li>
          </ol>
        </div>
        <div class="read-more" onclick="toggleContent('custom-card-2')">Read More üç™</div>
      </div>

      <!-- END OF PRACTICE QUESTIONS CONTAINER -->


      <!-- CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
      <div class="contact">
        <div class="comment-container">
          <div class="comment-icon">
            <!-- Add your icon image here -->
            <img src="../images/icons/comment.png" alt="Comment Icon">
          </div>
          <div class="comment-text">
            <!-- Add your text here -->
            <p>Send your comments, corrections, explanations/clarifications and requests/suggestions </p>
          </div>
          <a href="https://docs.google.com/forms/d/e/1FAIpQLSdx2teDCmW6ivSeKLQg7zF_jy7Yfg_1Gqm84_UT0PQPATsNug/viewform?usp=sf_link" class="comment-button">
            here
            <!-- <img src="../images/icons/whatsapp.png" alt="Image Icon"> -->
          </a>
        </div>

        <div class="contributors-container">

          <h2 class="contributors-header">Contributors</h2>
  
        <br>
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/woman.png" alt="Contributor 1 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">Jane Smith</h3>
                    <p class="contributor-description">She is not a real contributor.</p>
                    <div class="social-links">
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                        </a>
                        <a href="#" target="_blank" class="social-icon">
                            <img src="../images/icons/twitter.png" alt="Social Icon 2">
                        </a>
                    </div>
                </div>
            </div>
        
            <div class="contributor-box">
                <img class="contributor-avatar" src="../images/icons/man.png" alt="Contributor 2 Avatar">
                <div class="contributor-info">
                    <h3 class="contributor-name">John Doe</h3>
                    <p class="contributor-description">He is not a real contributor.</p>
                    <div class="social-links">
                      <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/whatsapp.png" alt="Social Icon 1">
                    </a>
                    <a href="#" target="_blank" class="social-icon">
                        <img src="../images/icons/linkedin.png" alt="Social Icon 2">
                    </a>
                    </div>
                </div>
            </div>
        
        </div>
      </div>

            <!-- END OF CONTACT- COMMENT AND CONTRIBUTORS CONTAINER -->
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p id="popup-trigger">disclaimer</p>

          <!-- The pop-up dive content -->
          <div id="popup" class="popup">
            <p>The contents on this ‚Äòwebsite‚Äô are for educational purposes only. The creators and operators of this website make no warranties, express or implied, regarding the accuracy, currency, or completeness of the information provided on the website. They shall not be held responsible for any errors or omissions, or for any actions taken based on the information provided on this website.</p>
            <button class="popup-close" onclick="closePopup()">Close</button>
          </div>    
          <p><a href="../about-temp2.html">about</a> </p>   
          <p><a href="../contribute.html">contribute</a> </p>
        </div>

        <div class="footer-beta">
          <p>thisisatestversion</p>
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="../main.js"></script>
<script src="../modal.js"></script>
<script src="../notes-sidebar.js"></script>
</body>
</html>
 
